MannKind Corporation (MNKD)
NASDAQ: MNKD · Real-Time Price · USD
3.630
+0.060 (1.68%)
At close: Jun 10, 2026, 4:00 PM EDT
3.580
-0.050 (-1.38%)
After-hours: Jun 10, 2026, 7:49 PM EDT
MannKind Employees
As of December 31, 2025, MannKind had 592 total employees, including 591 full-time and 1 part-time employees. The number of employees increased by 185 or 45.45% compared to the previous year.
Employees
592
Change (1Y)
185
Growth (1Y)
45.45%
Revenue / Employee
$609,431
Profits / Employee
-$40,395
Market Cap
1.12B
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2025 | 592 | 185 | 45.45% | 591 | 1 |
| Dec 31, 2024 | 407 | -7 | -1.69% | 403 | 4 |
| Dec 31, 2023 | 414 | 19 | 4.81% | 411 | 3 |
| Dec 31, 2022 | 395 | 46 | 13.18% | 391 | 4 |
| Dec 31, 2021 | 349 | 108 | 44.81% | 348 | 1 |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Sep 30, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Pharming Group | 407 |
| Wave Life Sciences | 317 |
| EyePoint | 214 |
| Zenas BioPharma | 167 |
| DBV Technologies | 161 |
| Absci | 140 |
| Jade Biosciences | 55 |
| Corvus Pharmaceuticals | 37 |
MNKD News
- 5 days ago - Data at ADA 2026 Highlights Key Findings from Clinical and Real‑World Studies of MannKind's Afrezza® (Inhaled Insulin) Across Pediatric Care, Pregnancy, and Use with Automated Insulin Delivery (AID) Systems - GlobeNewsWire
- 7 days ago - MannKind Transcript: Jefferies Global Healthcare Conference 2026 - Transcripts
- 7 days ago - MannKind announces milestones in development of nintedanib DPI for IPF - TheFly
- 7 days ago - MannKind Enters Data-Rich Development Period with Completion of Randomization in Phase 1b INFLO-1 Study and Enrollment of First Patient in Phase 2 INFLO-2 Trial for Nintedanib DPI in Patients with IPF - GlobeNewsWire
- 10 days ago - MannKind price target raised to $11 from $10 at Wells Fargo - TheFly
- 12 days ago - MannKind Transcript: FDA announcement - Transcripts
- 12 days ago - MannKind to Host Conference Call Today to Discuss Afrezza Pediatric Approval - GlobeNewsWire
- 12 days ago - US FDA approves MannKind's inhaled insulin for children - Reuters